PARIS, May 10 (Reuters) - Sanofi on Friday

announced it has reached a 'co-exclusive' licensing agreement

with Novavax ( NVAX ) to sell a stand-alone COVID-19 vaccine and

develop new flu-COVID-19 combination vaccines.

"We're excited by the prospect of combining Novavax's ( NVAX )

adjuvanted COVID-19 vaccine that has shown high efficacy and

favorable tolerability, with our rich portfolio of

differentiated flu vaccines (...)", Sanofi's head of vaccines

R&D, Jean-Francois Toussaint, said in a statement.